N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=10 Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours
Liver Tumour
Primary: Concentration of Total Intratumoral Doxorubicin in Liver Tumour (Biopsies) Following Targeted Release of Doxorubicin From ThermoDox® ('Drug') Using Mild Hyperthermia…
Phase 2 N=25 Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)
Liver Cancer
Primary: Number of Participants With Toxicity Related to Electrochemotherapy — 20; 0; 0; 4 Participants
Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Phase 2 N=3 Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
Liver Cancer · Liver Neoplasm · Hepatocellular Carcinoma
Primary: Number of Participants for Which Uptake of [18F]-FMISO Was Successful and Hypoxic Tumors Were Observed During PET Scan Imaging Post TACE Procedure — 0 Participants
Phase 2 N=39 Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
Liver Cancer
Primary: Tumor Response by Response Evaluation Criteria in Solid Tumors (RECIST) — 1; 1; 17; 15 Participants
N/A N=8 Contrast Sonography for Evaluation of Liver Tumors Prior to Radiofrequency Ablation
Liver Neoplasms
Primary: Percent of Tumors With Increased Echogenicity (Brightness) Following Contrast-enhanced Sonography — 8 tumor
Phase 2 N=50 Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Liver Cancer · Metastatic Cancer
Primary: Time to Progression — 2.3; 7.2 Months
Phase 2 N=18 Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Dose-limiting Toxicities (DLT) and Maximum Tolerated Dose (MTD) of Belinostat in Patients With Inoperable HCC (Phase I) — 0; 0; 0; 1 Participants
N/A N=84 Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
Hepatocellular Carcinoma · HCC
Primary: SubStudy 1: Apparent Diffusion Coefficient (ADC) — 1.43 1x10^-3 mm^2/s
N/A N=7 Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer
Liver Cancer
Primary: The Safety of Hypofractionated Stereotactic Radiotherapy in Patients With Advanced Hepatocellular Carcinoma — 0; 0; 1; 3 Participants
Phase 2 N=23 A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
Advanced Hepatocellular Carcinoma · HCC · Liver Cancer
Primary: Time to Disease Progression — 8 months
Phase 2 N=61 Tremelimumab With Chemoembolization or Ablation for Liver Cancer
Heptocellular Cancer · Biliary Tract Neoplasms · Liver Cancer
Primary: Number of Participants With Serious and Non-Serious Adverse Events Regardless of Attribution — 8; 12; 12; 9 Participants
Phase 2 N=64 PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
Adult Hepatocellular Carcinoma · Localized Resectable Adult Liver Carcinoma
Primary: Fluorine-18 (18F) Fluoromethylcholine (FCH) PET/CT Parameters for Assessing Hepatocellular Carcinoma (HCC): Area Under the Receiver Operating Characteristic Curve…
N/A N=14 Advanced Image Guidance Utilized in Liver Surgery
Carcinoma, Hepatocellular
Primary: Successful Insertion of Ablation Antenna Into Target Lesion — 100 percentage of participants
N/A N=20 Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Adult Hepatocellular Carcinoma · Advanced Adult Hepatocellular Carcinoma · Localized Non-Resectable Adult Liver Carcinoma
Primary: Severe Treatment-related Toxicity — 0 Participants
Phase 2 N=151 TheraSphere for the Treatment of Liver Metastases
Colorectal Cancer · Carcinoma, Neuroendocrine · Neoplasm Metastasis
Primary: Hepatic Progression-free Survival According to Response Evaluation Criterian in Solid Tumors (RECIST) — 3.0; 17.9; 2.9; 3.4 Months
N/A N=84 Liver Fat Quantification by Magnetic Resonance Imaging (MRI) - Prediction of Postoperative Complications
Fatty Liver · Surgery
Primary: Percentage of Liver Fat Content on MRI in Patients With Serious Post-operative Complications (Clavien-Dindo Grade ≥IV) — 1.3; 13.6 Percentage of liver fat content
Phase 2 N=19 Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Adult Primary Hepatocellular Carcinoma · Advanced Adult Primary Liver Cancer · Localized Unresectable Adult Primary Liver Cancer
Primary: Number of Participants With Radiographic Objective Response (OR) — 0 participants
Phase 2 N=33 Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery
Advanced Adult Hepatocellular Carcinoma · Non-Resectable Hepatocellular Carcinoma
Primary: PFS, Assessed Using Standard RECIST Criteria — 58 percentage of participants
Phase 2 N=26 Study of Pembrolizumab Following TACE in Primary Liver Carcinoma
Primary Liver Carcinoma
Primary: Incidence of Treatment-emergent Adverse Events (Safety and Tolerability) — 15 Participants
N/A N=3,800 Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs
Cancer
Primary: Number of Patients With ALT (Alanine Transaminase) >=3x (Times) Upper Limit of Normal (ULN) — 11 participants
Phase 2 N=23 Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II
Liver Metastases
Primary: Evaluation of Safety Related to Electrochemotherapy — 20; 3; 0; 0 Participants
N/A N=51 Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis
Liver Cancer
Primary: Proportion of Participants With Successful Control of Disease at 18 Months — .18 proportion of participants
N/A N=77 Dose Escalation Study for Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants
N/A N=105 Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration
Hepatocellular Carcinoma
Primary: Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study. — 21; 29; 14; 9 participants — p=< 0.005
Phase 2 N=22 Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Liver Cancer
Primary: Median Overall Survival — 31.1 months
Phase 2 N=11 Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Liver Cancer
Primary: Number of Subjects Experiencing Adverse Events — 2 participants
Phase 2 N=5 [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer
Adult Liver Carcinoma · Liver Cirrhosis
Primary: Post-treatment Maximum Standardized Uptake Value (SUVmax) in Tumor and Normal Tissue — 0.76 Ratio
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months